Acuamark develops technology that allows for highly accurate screening of blood to detect cancer markers at early cancer stages.
Acuamark Diagnostics has raised $11.6M in total funding. The most recent round was Series A. The last funding was announced in April 2022.
Acuamark Diagnostics's investors include 1289 Capital, Claudio Del Vecchio.
Acuamark Diagnostics is headquartered in New York, United States.
Acuamark develops technology that allows for highly accurate screening of blood to detect cancer markers at early cancer stages.
Acuamark Diagnostics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Acuamark Diagnostics — Funding & Investors." VCBacked, April 6, 2022, https://www.vcbacked.co/company/acuamark-diagnostics. Accessed August 23, 2026.
VCBacked. (2022). Acuamark Diagnostics — Funding & Investors. Retrieved August 23, 2026, from https://www.vcbacked.co/company/acuamark-diagnostics
{{cite web |title=Acuamark Diagnostics — Funding & Investors |url=https://www.vcbacked.co/company/acuamark-diagnostics |website=VCBacked |access-date=August 23, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated